Company / EPS (Diluted)
CytomX Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.16
FY2017
5-year range
-
FY2016-FY2017
Trend
+28.8%
vs FY2016
Sector context
#97 of 204
Health Care
What the data says
At $-1.16, CytomX Therapeutics, Inc.'s eps (diluted) ranks #97 of 204 in the Health Care sector.
Based on SEC 10-K filings.
-1.16 in FY2017.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#97 of 204 in Health CareTop 48% of 204This company -$1.16 Sector average -$0.89
▼
-30.9% below sector average
Key checks
Key Insights
- In FY2017, eps (diluted) increased 28.8% year-over-year.
- Ranks #97 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -$1.16 | +28.8% |
| FY2016 | -$1.63 | +93.3% |
As of FY2017 · SEC 10-K · Updated Jul 2, 2026